Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP

Filed by OGR.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2025
Income
$20,000.00
Expenses
Not reported
Registrant
OGR
Filing UUID
ce9dccad-9674-4e00-b912-1a463699b30e
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act.

Literal federal measure citations: H.R.1796

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.